Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Herald Therapeutics
Palo Alto, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Herald Therapeutics is a clinical-stage biotechnology company and a subsidiary of BridgeBio Pharma, focused on developing therapies for rare lysosomal storage disorders. The company's lead program, HLD-204, is an investigational small molecule pharmacological chaperone designed to treat Mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome type B. HLD-204 works by binding to and stabilizing the mutant N-acetyl-alpha-glucosaminidase (NAGLU) enzyme, potentially restoring its activity and reducing the accumulation of toxic heparan sulfate. Herald Therapeutics leverages BridgeBio's centralized resources to accelerate the development of this potentially disease-modifying oral treatment. The company was founded based on research from the University of Pennsylvania and aims to address the significant unmet medical need in pediatric neurodegenerative conditions.
- Therapeutic areas
- Rare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Herald Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Herald Therapeutics.